Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06828796 · ClinicalTrials.gov registry record · Phase 2
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
A Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06828796 is a Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 386-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06828796, a Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Mycofenolate mofetil
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06828796
The ClinicalTrials.gov registry entry for NCT06828796 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (95% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic Cell Transplant appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06828796 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06828796 about?
NCT06828796 is a clinical study titled "Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide". To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
What is the current status of trial NCT06828796?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-07-03. Estimated completion is 2028-06-30.
What conditions does trial NCT06828796 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplant, Hematologic Disease and Disorders.
What interventions are being tested in trial NCT06828796?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Mycofenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT06828796?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06828796 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
RECRUITING
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
RECRUITING · NA
-
Virtual Rehabilitation in HCT
RECRUITING · NA
-
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
ACTIVE NOT RECRUITING
-
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
COMPLETED
Explore more on PlainTrial
Hematopoietic Cell Transplant
All registered trials for this condition
Hematologic Disease and Disorders
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.